Crohn's Disease
Pipeline by Development Stage
Drug Modality Breakdown
Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.
Key Trends
- JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
- Multiple patent cliffs emerging 2026-2028, creating generic competition risk
- Robust pipeline with 4,996 trials signals continued innovation and market expansion
Career Verdict
Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (TIRZEPATIDE) | Eli Lilly and Company | $2.4B | 16% | PEAK | Growing | 15.5yr |
| 2 | SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) | AstraZeneca | $2.0B | 13% | LOE_APPROACHING | Stable | |
| 3 | JAKAFI (RUXOLITINIB) | Incyte | $1.9B | 13% | LOE_APPROACHING | Declining | 2.5yr |
| 4 | RESTASIS (CYCLOSPORINE) | AbbVie | $1.5B | 10% | PEAK | Stable | 7.9yr |
| 5 | RINVOQ (UPADACITINIB) | AbbVie | $976M | 7% | PEAK | Growing | 11.7yr |
Drug Class Breakdown
dominant class with patent cliff risk
established, mature market segment
driven by single blockbuster
established immunosuppression class
legacy biologic class with competition
Career Outlook
GrowingImmunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.
Breaking In
Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.
For Experienced Professionals
Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.
In-Demand Skills
Best For
Hiring Landscape
Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.
Top Hiring Companies
By Department
Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.
On Market (2)
Approved therapies currently available
Competitive Landscape
59 companies ranked by most advanced pipeline stage
+29 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 13,635 patients across 50 trials
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Risankizumab Long-term Remission Study
A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula
Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
Triple Combination Therapy in High Risk Crohn's Disease (CD)
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Corticosteroids With Vedolizumab in Crohn's Disease
Does Clinical Response Correlate With Serum Certolizumab Levels?
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
Top-down Infliximab Study in Kids With Crohn's Disease
Cimzia Versus Mesalamine for Crohn's Recurrence
Trial of a Treatment Algorithm for the Management of Crohn's Disease
Optimizing Cimzia in Crohn's Patients
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
Treatment With Infliximab in a Medical Setting (Study P05587)
A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease
Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease
Safety of Celecoxib in Patients With Crohn's Disease
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
Related Jobs in Immunology
Sr. Manager/ Associate Director, Biostatistics
Senior Research Executive
CTM / Sr CTM Internal Medicine
Clinical Sales Specialist
Senior Research Executive
Quality Compliance Engineer
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.